Reference Standards | Research Chemicals | Research Services


§Bortezomib was originally made in 1995 at Myogenics. 
§Bortezomib is also FDA-approved for use in the treatment of multiple myeloma & mantle cell Lymphoma.
§Bortezomib is a dipeptide Boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.
§Bortezomib has a role as an antineoplastic agent, a proteasome inhibitor, a protease inhibitor and
an antiprotozoal drug.
Proteasomes are in cells. They help to break down proteins that the cell doesn't need. Bortezomib b blocks the proteasomes so the proteins build up inside the cell. The cell then dies.  
§A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
Bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.
Enquire Now